by Ken Pishna – MMAWeekly.com
Aside from Kazuhiro Nakamura’s previously announced suspension for testing positive for marijuana, the 17 remaining competitors from Sept. 22’s Ultimate Fighting Championship event in Anaheim, Calif. were clean on their drug tests, both for drugs of abuse and for anabolic agents/masking agents, according to Bill Douglas, a representative of the California State Athletic Commission.

Nakamura lost a unanimous decision to Lyoto Machida at UFC 76. He was subsequently fined $500 and suspended from the conclusion of the bout on Sept. 22, 2007 through Dec. 21, 2007.

According to Zach Arnold of FightOpinion.com, however, Nakamura’s management team, J-ROCK, is appealing the CSAC ruling and considers the drug test result a mistake.

The basis of their argument appears to be concern in regards to an MRI that was conducted as part of post-fight precautionary measures ordered by the commission. The testing is standard procedure following a “hard fight” according to Armando Garcia, executive director of the CSAC.

Garcia relayed that Nakamura was kept overnight in the Intensive Care Unit because of what representatives at the hospital said appeared to be abnormal results on his MRI and a possible subdural hematoma (commonly referred to as bleeding on the brain).

The next day “the neuro surgery team evaluated him and determined that he did not have one,” said Garcia. “He was subsequently released.”

According to Arnold’s recount with J-ROCK, “Nakamura flew back to Japan … and was examined by a Japanese doctor. The results of the Japanese tests were different than the American hospital’s test results (the Japanese testing did not show bleeding in the brain).

“Therefore, J-ROCK’s public stance is that there were mistakes with other medical tests and that there must have been a mistake with the CSAC drug test. They do not accept the current findings from the initial CSAC drug test.”